FDA accepts BLA from AstraZeneca and Daiichi for targeted chemotherapy
AstraZeneca and Daiichi have been collaborating on targeted chemotherapy products since March this year. Credit: Shutterstock.
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.ContinueLearn more